A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
一项针对晚期非小细胞肺癌患者的Ib/II期研究,评估cadonilimab(PD-1/CTLA-4双特异性抗体)联合anlotinib一线治疗的疗效。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-023-02519-0
Chen, Bolin; Yao, Wenxiu; Li, Xingya; Lin, Gen; Chu, Qian; Liu, Hailong; Du, Yingying; Lin, Jie; Duan, Huaxin; Wang, Huijuan; Xiao, Zemin; Sun, Hong; Liu, Liyu; Xu, Li; Xu, Yan; Xu, Fang; Kong, Yi; Pu, Xingxiang; Li, Kang; Wang, Qianzhi; Li, Jia; Li, Baiyong; Xia, Yu; Wu, Lin